JNJ

Business Profile & Competitive Position

Johnson & Johnson is a holding company whose subsidiaries employ approximately 138,200 people worldwide and are engaged in the research, development, manufacture, and sale of healthcare products. The company operates through two business segments: Innovative Medicine, which focuses on prescription therapeutics in Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism; and MedTech, which develops products used in cardiovascular, orthopaedics, surgery, and vision procedures. Those products are distributed to retailers, wholesalers, distributors, hospitals, eye-care professionals, and healthcare professionals in virtually all countries of the world.

The numbers argue for a wide-moat, capital-efficient franchise. With a market capitalization of $646.0B, a net margin of 21.5%, and a return on equity of 25.7%, JNJ sits well above the profitability thresholds typical of the average large-cap company. A 21.5% net margin implies strong pricing power and disciplined cost absorption across both pharmaceuticals and devices, while a 25.7% ROE indicates the business is generating material profit on the equity it has deployed. The beta of 0.23 confirms the low-volatility profile normally associated with defensive healthcare compounders.

Financial Posture

JNJ currently trades at $268.05 on a trailing P/E of 31.0. The RSI is 51.5, a neutral reading, and the 50-day EMA is $261.82, so the stock is sitting just a few dollars above a widely watched near-term trend level. A P/E of 31.0 is not cheap in absolute terms, but it sits against the backdrop of a 21.5% net margin and a 25.7% ROE—profitability metrics that help explain why the market assigns a premium multiple. The 0.23 beta is especially relevant for risk budgeting: historically, the stock has moved far less than the overall market, which is consistent with a healthcare giant that derives revenue from recurring pharmaceutical demand and entrenched medical-device lines. No debt figure was supplied in the data, so leverage cannot be evaluated here.

Strategic Priorities & Outlook

The company’s most recent 10-K lays out several priorities. The most significant near-term event is the planned separation of the Orthopaedics business, announced in October 2025, with a targeted completion within 18 to 24 months. That carve-out would materially reshape the MedTech segment and could refocus capital on faster-growing or higher-margin areas. Separately, management emphasizes a human-capital strategy built on attracting, developing, retaining, and empowering talent, supported by programs such as J&J Learn and the annual Global Learning Day, all framed within a Credo-based culture of innovation, health, well-being, safety, inclusion, and belonging.

Revenue concentration is also disclosed. DARZALEX/DARZALEX FASPRO accounted for approximately 15.0% of 2025 total revenues, STELARA for approximately 6.5%, and TREMFYA for approximately 5.5%. That makes oncology and immunology central to the near-term revenue story. At the same time, the filing explicitly warns that continued global launches of biosimilar versions of STELARA are expected to keep pressuring STELARA sales. The company also notes that worldwide sales do not reflect significant seasonality, but fourth-quarter spending is typically heavier, driven mainly by advertising and research-and-development decisions.

Macro & Geopolitical Exposure

As a Drug Manufacturers - General company in the Healthcare sector, JNJ is exposed to several structural macro themes. Regulatory risk is front and center: FDA approvals, labeling changes, manufacturing inspections, and safety reviews can all affect revenue trajectories and margin assumptions. Drug-pricing policy—whether via Medicare negotiation, Medicaid rebating, or international reference pricing—can directly constrain realized pricing power. Patent cliffs and biosimilar competition, already flagged for STELARA, are recurring industry dynamics that can erode blockbuster franchises faster than cost cuts can compensate. Currency exposure is meaningful because products are sold in virtually all countries, so a stronger U.S. dollar can compress reported results. Supply-chain reliability for active pharmaceutical ingredients and medical-device components remains a persistent concern, as does trade policy affecting cross-border manufacturing and tariffs.

Recent Developments

The most recent news flow, dated September 14, 2026, was dominated by income-oriented and institutional-positioning stories rather than fundamental product or regulatory news. 247wallst.com published two dividend-focused articles—“Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA” and “How Much You Need Invested to Cover Your Medicare Premiums With Dividend Income”—reflecting JNJ’s continuing role in retirement-income and tax-planning discussions. On the same day, defenseworld.net reported that Maloon Powers Pitre Higgins & Dennehy LLC had taken a new stake in Johnson & Johnson, while NBH Bank purchased 11,346 shares. These disclosures are small in the context of a $646.0B company, but they illustrate ongoing institutional accumulation and the ticker’s place in long-horizon portfolios.

Earnings Behavior & Post-Earnings Drift

JNJ has beaten earnings expectations in 7 of the last 8 reported quarters; the only non-beat in that window was an inline result, not a miss. The average earnings surprise across those eight quarters is 3.4%. In the five trading days following each report, the stock has averaged a 0.67% gain, classified as an “up” post-earnings drift. That pattern is relatively muted—consistent with the 0.23 beta—but it does indicate the market has typically underreacted to results rather than reversing them.

The last four quarters reveal the nuance behind the averages. On July 15, 2026, JNJ reported $2.90 against a $2.84 estimate (a 2.1% surprise) and the stock rose 1.19% the next day and 3.49% over the following five days. On April 14, 2026, the company beat by 0.7% with $2.70 versus $2.68, yet the stock fell 0.60% the next day and 5.81% over the following five days—an important reminder that beats do not guarantee post-report upside. The January 21, 2026 quarter was inline at $2.46, posting a 0.22% next-day move but a 4.45% five-day drift. The October 14, 2025 report delivered $2.80 against $2.76 (1.4% surprise), producing a 0.17% next-day move and a 0.54% five-day move. The next scheduled report is October 13, 2026 before the open, with the consensus EPS estimate at $2.90—the same level JNJ actually delivered in July.

For a deeper dive into institutional conviction, sector positioning, and how analysts are framing the October 13 report, take a look at the full institutional verdict on JNJ.